Endpoints News

Anthropic pays $400M for biotech; Praxis epilepsy drug hits in Phase 1/2 trial

Plus: Debt financing deals for Apnimed and Opus Genetics

This report was first published by Endpoints News. To see the original version, click here

Plus: Debt financing deals for Apnimed and Opus Genetics

Anthropic buys a stealth biotech: The San Francisco artificial intelligence giant is buying Coefficient Bio, building out its plans to bring AI into life sciences. Anthropic agreed to pay $400 million in stock for Coefficient, which was founded less than a year ago. Dimension Capital was the stealth startup’s top investor and is posting an over 21-times return on invested capital, based on Anthropic’s latest valuation of $380 billion, according to a letter sent to Dimension’s limited partners and viewed by Endpoints News. — Andrew Dunn

您已阅读32%(687字),剩余68%(1486字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归Endpoints News所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×